Genmab A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMAB research report →
Range $40 – $70
Price Chart
About the company
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis.
- CEO
- Jan van de Winkel
- IPO
- 2009
- Employees
- 3,244
- HQ
- Copenhagen, CD, DK
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend and remains well above its 200-day average, signaling a sustained recovery regime. It is still below the 52-week high, so the setup favors a stock that has repaired sharply but has not yet fully reclaimed prior peak territory.
Wall Street stays constructive, with a Buy consensus and a $50.83 target versus a $51.52 share price, leaving the stock near fair value on consensus. Recent action has leaned positive, with multiple target raises in October and no meaningful wave of downgrades.
Earnings momentum has improved, with two straight beats after two misses, including a 55.6% EPS beat in the latest quarter. Next-year EPS is expected to rise to 1.7273 from 1.17 TTM, so shareholders should watch whether revenue growth and margin discipline keep supporting that path.
No notable insider buying or selling in recent quarters. The absence of discretionary transactions keeps the focus on operating results and pipeline execution rather than insider signaling.
Profitability is solid for a biotech name, with a 92.7% gross margin, 30.6% operating margin, and 16.97% net margin. Revenue grew 16.1% year over year, while free cash flow reached $1.22 billion, giving the business real operating leverage.
Genmab stands out for high margins and a diversified antibody franchise, but its valuation is richer than many peers at 38.82 times earnings. The market is paying for durable growth, though the balance sheet carries $3.71 billion in net debt, which tempers the premium.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.20B
- P/E
- 43.21
- Fwd P/E
- 40.29
- PEG
- -0.51
- P/S
- 7.35
- P/B
- 4.97
- EV/EBITDA
- 25.30
- Div Yield
- 0.00%
- Gross Margin
- 92.60%
- Op Margin
- 30.53%
- Net Margin
- 16.95%
- ROE
- 12.26%
- ROIC
- 10.27%
Latest fiscal year · YoY change
- Revenue
- $3.72B-82.7%
- Gross Profit
- $3.41B-83.4%
- Op Income
- $1.25B
- Net Income
- $963.76M-87.7%
- EPS
- $1.55-87.3%
- OCF Growth
- -84.7%
- FCF Growth
- -84.8%
- 52W High
- $59.97
- 52W Low
- $23.62
- 50D MA
- $42.62
- 200D MA
- $31.92
- Beta
- 0.65
- RSI (14)
- 56
- Avg Volume
- 4.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Genmab delivered 22% revenue growth and 9% adjusted operating profit growth in the first nine months of 2026, while three positive phase III readouts strengthened the long-term pipeline.· November 5, 2026
- Revenue rose 22% in the first nine months, with growth coming broadly from DARZALEX, EPKINLY, and the rest of the portfolio.
- Adjusted operating profit increased 9% despite continued investment in late-stage development and launch readiness.
- Management highlighted three major October phase III wins for EPKINLY, Rina-S, and petosemtamab, each reinforcing the company’s late-stage growth story.
- 2026 guidance was maintained, and management said revenue is now expected toward the upper end of the range while Q4 operating expenses should step up materially.
- The company reiterated long-term peak sales targets, including more than $3 billion for EPKINLY, more than $2 billion for Rina-S, and multi-billion for petosemtamab.
For the first nine months of 2026, Genmab said total revenue increased 22% year-over-year, with DARZALEX up 19%, worldwide EPKINLY net product sales up 47%, and the remainder of the portfolio up 30%. Adjusted operating profit rose 9% year-over-year. EPKINLY sales reached $491 million in the first nine months, and TIVDAK sales totaled $131 million, up 9% year-over-year. The effective tax rate for the first nine months was 3.4%, mainly due to Merus integration and related deferred tax asset recognition and utilization. For full-year 2026, Genmab maintained guidance for revenue of around $4.325 billion-$4.525 billion, operating expenses of around $2.81 billion-$2.95 billion, and adjusted operating profit of $1.065 billion-$1.35 billion. Management said revenue is tracking toward the upper end of guidance, OpEx should be around the midpoint of $2.88 billion, and Q4 OpEx will step up significantly due to manufacturing, clinical development, and launch readiness work.
Jan van de Winkel framed the quarter as a landmark period for both the business and pipeline. He emphasized that Genmab now has three high-quality late-stage programs with phase III results that he believes could change treatment standards, and he tied that to the company’s antibody expertise, ability to assess innovation, and speed of execution. His tone was highly confident and upbeat, while also stressing disciplined capital allocation and a goal of keeping gross leverage below 3x by the end of next year.
Anthony Pagano focused on the quality and diversification of revenue growth, noting that roughly half of revenue growth came from DARZALEX and the other half from EPKINLY and the rest of the portfolio. He stressed that the company can keep investing in launch readiness and the nine ongoing phase III trials for Rina-S and petosemtamab while still growing adjusted operating profit. He also said the effective tax rate of 3.4% should normalize over the next 12-18 months, and he reaffirmed 2026 guidance with revenue expected in the upper part of the range and OpEx around the midpoint.
Analysts focused heavily on the new phase III data, especially the OS interpretation for EPKINLY in frontline DLBCL, safety questions, and how the results affect launch timing and market positioning versus regimens like Pola-R-CHP. Management said the EPKINLY OS data are immature because follow-up was only 10 months, that there was no new safety signal, and that the frontline study’s positive PFS result would serve as the regulatory confirmatory trial. They also said the company is confident in petosemtamab’s multi-billion sales potential and $1 billion 2029 target, while noting Rina-S filing in endometrial is more likely to be based on the phase III data and that the recent PROC readout is already creating a recruitment halo effect.
The call reinforced that Genmab has both accelerating commercial momentum and a much stronger late-stage pipeline than before the October readouts. Management sounded confident that EPKINLY can expand into earlier lines, that Rina-S can become a major gynecologic oncology franchise, and that petosemtamab may become a practice-changing solid tumor asset. They also believe the business can keep growing revenue and profits at the same time.
The biggest near-term risks are execution and timing: the key EPKINLY OS data are still immature, several planned filings and launches depend on future regulatory steps, and Q4 operating expenses will rise sharply as development and launch activity picks up. Analysts also pressed on competitive and commercial questions in DLBCL, colorectal cancer, and endometrial cancer, showing that the market opportunity is still being tested against existing standards and rival programs. Management’s long-term targets remain high, but much of the valuation thesis still depends on upcoming follow-up and broader data presentation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.5%
- Shares Outstanding
- 616.59M
- Float Shares
- 589.06M
of shares held by institutions
307 13F filers
Congressional trading
Senate and House stock disclosures for GMAB, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jan 16, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 16, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 19, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 18, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 20, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 19, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Mar 31, 23 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Paradigm Biocapital Advisors LP | 13.13M | ▲ 5.17M |
| Orbis Allan Gray Ltd | 11.37M | ▼ 1.56M |
| Alliancebernstein L.P. | 8.64M | ▼ 912.27K |
| Deerfield Management Company, L.P. | 6.87M | ▲ 4.40M |
| Arrowstreet Capital, Limited Partnership | 6.07M | ▲ 1.09M |
| Blackrock, Inc. | 6.06M | ▲ 1.39M |
| Deep Track Capital, LP | 5.65M | ▲ 1.99M |
| Sofinnova Investments, Inc. | 4.05M | ▲ 3.29M |
| Capital World Investors | 3.90M | ▲ 3.90M |
| Two Sigma Investments, LP | 3.51M | ▲ 1.17M |
| First Trust Advisors LP | 3.23M | ▲ 469.12K |
| Harding Loevner LP | 3.09M | ▼ 145.28K |
Held by 95 ETFs
Biggest fund positions in GMAB by dollar value.
Our GMAB coverage
Recent articles, reports, and earnings notes.

Genmab (GMAB): EPKINLY Growth vs. Royalty Dependence
Genmab is shifting from a royalty-led model toward proprietary growth, with EPKINLY driving strong sales gains and late-stage oncology assets offering a path to diversify revenue. The stock looks attractive for investors who can tolerate patent-expiry and pipeline-execution risk.

Genmab A/S (GMAB) jumps 16% on petosemtamab data
Genmab A/S (GMAB) jumps after updated Phase 2 petosemtamab data in metastatic colorectal cancer boosted confidence in its oncology pipeline. The move came on heavier-than-usual volume and followed recent positive clinical and analyst developments that strengthened the company’s growth outlook.

Veraxa Biotech AG IPO: What Investors Need to Know
Veraxa Biotech AG Ordinary Shares (NASDAQ: VRXA) is expected to list on 2026-06-10, but the price range has not been disclosed. This is a SPAC business combination rather than a traditional IPO, with the story centered on a pre-commercial oncology pipeline. Bull case: a differentiated antibody-therapy platform; bear case: no product revenue yet and heavy financing needs.
Want a deeper read on GMAB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Grant of Restricted Stock Units and Warrants to Employees in Genmab
globenewswire.com · Nov 18
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
fool.com · Nov 11
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
globenewswire.com · Nov 11
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
globenewswire.com · Nov 11
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
globenewswire.com · Nov 10
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com · Nov 10
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice